Business Wire

NORTHERN-DATA-AG

30.3.2020 08:44:06 CEST | Business Wire | Press release

Share
Northern Data: Corona / COVID-19 Pandemic Leading to Massive Uptick in Demand for Computing Capacity

Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world's largest providers of high-performance computing (HPC) solutions, today reports that the Corona Virus / COVID-19 -Pandemic is resulting in a massive increase in computing capacity demand. In order to meet the increased demand, the company has instigated an acceleration of the expansion of capacities at its locations and in addition is looking to develop further locations.

Immediate demand for computing power in the wake of the pandemic is being driven by two immediate and game changing developments: Firstly, pharmaceutical companies and research institutions worldwide are using HPC systems on a large scale for the first time in order to carry out calculations and simulations in the field of bioinformatics and epidemiology in the shortest possible time, which with conventional computer systems can take several months or even years. This gives research teams the opportunity to accelerate the development of novel drugs that can be used against the coronavirus in the short term. Northern Data management expects this trend to continue after the end of the COVID 19 pandemic.

Secondly working conditions worldwide have shifted drastically online in a matter of weeks through the course of the COVID 19 pandemic, this has led to a massive increase in demand for computing capacity. Due to the current restrictions, many companies in parts of the United States, Europe and Asia are forced to operate with an almost 100% home office ratio. The associated use of digital applications such as video conferencing tools is causing an explosion in demand for data capacities. Also, this trend will continue beyond the corona crisis.

Northern Data will start operating its newest HPC facility in the United States in the coming days. The world's largest HPC data center is being built in Texas on an area of ​​more than 100 acres, which corresponds to the size of around 57 soccer fields. The company originally intended to achieve a total capacity of one gigawatt at the US location by the end of the year. Due to the changed and overwhelming demand situation, plans are now beginning to seamlessly expand the location to up to 3.6 gigawatts.

The company is also accelerating the development of additional locations for additional large-scale HPC facilities in Canada and Scandinavia.

"We are facing overwhelming demand," said Aroosh Thillainathan, CEO of Northern Data AG. "In some areas we see a thirty times higher market demand than we can build up capacities by the end of the year. We now benefit from our many years of experience in large-scale high-performance computing in order to further accelerate ongoing scaling."

Northern Data published its forecast for 2020 on March 16. Based on current expectations and in line with contracts already signed, the Management Board expects revenues of EUR 120 million to EUR 140 million in the course of 2020. Accordingly, the Management Board expects EBITDA of between EUR 45 million and EUR 60 million. This guidance is based only on a partial utilization of initially 30% of the 1GW expansion stage, based on already concluded contracts for the provision of HPC solutions with global customers. The forecast will be adjusted in due course as new customer acquisition progresses.

About Northern Data:

Northern Data AG develops and builds global infrastructure solutions in the area of ​​high-performance computing (HPC). The company offers solutions in areas such as machine learning and artificial intelligence, big data analytics, blockchain, game streaming and others. The international company emerged from the merger of the German Northern Bitcoin AG and the American Whinstone US, Inc. and is today a recognized market leader in the field of HPC solutions worldwide. Northern Data offers its HPC solutions both stationary in large, state-of-the-art data centers and in mobile, high-tech data centers based on containers, which can be set up at any location worldwide. It combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. In Texas, Whinstone is currently building the largest HPC data center in the United States and the largest facility in the world specifically for HPC applications.

Language: English
Company: Northern Data AG
Thurn-und-Taxis-Platz 6
60313 Frankfurt/Main
Germany
Phone: +49 69 34 87 52 25
E-mail: info@northerndata.de
Internet: www.northerndata.de
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate
Exchange

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye